Ticagrelor

Amber-G

Brand Name(s):Brilique , Possia

Indication:Prevention of atherothrombotic events in patients with acute coronary syndrome (including STEMI, NSTEMI and unstable angina)
Myocardial infarction (MI)-history of, with a high risk of developing an atherothrombotic event

Rationale:

Considered:Nov-11

Review Date:Jan-22

Comments:
Ticagrelor for preventing atherothrombotic events after myocardial infarction
December 2016
…………………………
NICE CG 172
MI Secondary Prevention
details at: http://www.nice.org.uk/nicemedia/live/14302/65691/65691.pdf
Issued November 2013
…………………………
NICE CG 167
The acute management of myocardial infarction with ST-segment elevation
Full information at:http://www.nice.org.uk/nicemedia/live/14208/64410/64410.pdf
Issued: July 2013
…………………………

The 1st 28 days supply will be provided by the initiating Hospital
Duration is for 12months post event and details should be added to the repeat prescription to ensure review occurs at this point.
Renal function should be checked 4 weeks after initiation – it is anticapted that the Primary Care prescriber will undertake this monitoring unless the patient attends a followup Cardiology appointment within this time scale.
Mild to moderate dyspnoea may occur in a very small number of patients – if this occurs contact Cardiology directly
The concomitant use of ticagrelor with doses of simvastatin greater than 40 mg is not recommended
Appropriate clinical and/or laboratory monitoring is recommended when giving digoxin or cyclosporin concomitantly with ticagrelor – contact Cardiology for further advice.

APC May 2012